0.85Open0.85Pre Close0 Volume10 Open Interest3.00Strike Price0.00Turnover0.00%IV0.46%PremiumAug 16, 2024Expiry Date0.84Intrinsic Value100Multiplier24DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.62Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Corvus Pharmaceuticals Stock Discussion
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet